Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Business Wire
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that it is continuing discussions with Mylan N.V. (NASDAQ: MYL) regarding whether or not Mylan plans to move forward with the biosimilar to BOTOX® program. As previously disclosed, the expected decision date for Mylan is the later of April 30, 2020 or thirty days from the date that Revance provides Mylan with certain deliverables regarding the program. Revance will issue an update on the path forward for the program once Mylan’s decision has been reached.Mylan and Revance originally signed a collaboration and license agreement in February 2018 for the development and regulatory approval of a biosimilar to BOTOX®, to be followed with commercialization by Mylan in the U.S., Europe and applicable markets throughout th
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $8.00. They now have a "neutral" rating on the stock.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $20.00.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Needham & Company LLC from $18.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
RVNC
Earnings
- 5/9/24 - Beat
RVNC
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/3/24 - Form 8-K
- RVNC's page on the SEC website